期刊
BRITISH JOURNAL OF CANCER
卷 104, 期 5, 页码 741-745出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6606061
关键词
renal cancer; sunitinib; mTOR; VEGF
类别
Targeted therapy has radically altered the way metastatic renal cancer is treated. Six drugs are now licensed in this setting, with several other agents under evaluation. Sunitinib is currently the most widely used in the first line setting with impressive efficacy and an established toxicity profile. However, as further randomised studies report and as newer drugs become available this may change. In this review, we address our current understanding of targeted therapy in renal cancer. We also discuss areas in which our knowledge is incomplete, including the identification of correlative biomarkers and mechanisms of drug resistance. Finally, we will describe the major areas of clinical research that will report over the next few years. British Journal of Cancer (2011) 104, 741-745. doi:10.1038/sj.bjc.6606061 www.bjcancer.com Published online 25 January 2011 (C) 2011 Cancer Research UK
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据